Financial Data and Key Metrics Changes - The company reported full-year adjusted earnings per share of $10, exceeding initial guidance by $0.54, with total net revenues of $61.2 billion, surpassing guidance by over $2 billion [5][6] - Sales growth of 8.6% led to record net sales, exceeding previous peak revenue by more than $3 billion despite nearly $16 billion erosion from U.S. Humira [6][9] - Adjusted earnings per share for the fourth quarter were $2.71, $0.08 above guidance midpoint, with total net revenues of $16.6 billion, reflecting robust growth of 10% [32][33] Business Line Data and Key Metrics Changes - Immunology revenues reached approximately $8.6 billion in the fourth quarter, with Skyrizi sales of $5 billion (31.9% operational growth) and Rinvoq sales of nearly $2.4 billion (28.6% operational growth) [10][11] - Neuroscience full-year revenues exceeded $10.7 billion, with a quarterly revenue of over $2.9 billion, up 17.3% operationally, driven by Vraylar and Botox Therapeutic [16][17] - Oncology revenues were nearly $1.7 billion in the quarter, down 2.5% operationally, with Venclexta sales of $710 million, up 6.4% [19][20] Market Data and Key Metrics Changes - Global sales for Skyrizi in IBD reached approximately $6.4 billion in 2025, more than double the prior year performance [13][14] - The aesthetics market faced economic headwinds, with global sales of nearly $1.3 billion in the quarter, down 1.2% operationally [21][22] - The company anticipates total sales growth of 9.5% in 2026, driven by Skyrizi and Rinvoq, with combined sales expected to exceed $31 billion [7][8] Company Strategy and Development Direction - The company is focused on advancing its pipeline across all stages of development and has invested over $5 billion in new business development [6][7] - A voluntary agreement with the U.S. government aims to enhance patient access and affordability while committing $100 billion in U.S. R&D and capital investments over the next decade [9] - The company plans to leverage its diverse portfolio to deliver high single-digit revenue growth through 2029 [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong position to deliver robust growth despite headwinds from Humira erosion and pricing pressures [5][7] - The outlook for 2026 includes expectations for substantial sales growth driven by key products, with a focus on maintaining momentum in immunology and neuroscience [8][9] - Management highlighted the potential for long-term growth in neuroscience and oncology, with several promising assets in the pipeline [59][60] Other Important Information - The company anticipates a significant ramp for Vyalev, achieving blockbuster status as a treatment for Parkinson's [8][18] - The adjusted operating margin is expected to expand to approximately 48.5% in 2026, reflecting operational efficiencies [36] - The company expects to generate free cash flow of approximately $18.5 billion in 2026, supporting dividends and investments in business development [38][39] Q&A Session Summary Question: Details on the psychedelic therapy in development - Management highlighted the potential of the psychedelic therapy, noting its unique mechanism and observed high efficacy, with further readouts expected before phase III [42][43][44] Question: Insights on Skyrizi's performance in IBD - Management confirmed stable new patient starts for Skyrizi in both Crohn's and UC, with high capture rates despite competition, indicating strong market positioning [51][53][54] Question: Update on external innovation and business development - The company has invested over $8 billion in external innovation, focusing on early-stage opportunities to enhance its pipeline across core therapeutic areas [64][66] Question: Expectations for Rinvoq and lutikizumab phase III data - Management expressed optimism for Rinvoq's performance in treatment failure populations and highlighted lutikizumab's strong efficacy in phase II, anticipating meaningful results in phase III [68][69][70]